Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P D Hansten

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
The Annals of Pharmacotherapy|December 1, 1993
Comment: pitfalls in reporting drug interactionsJ R Horn, P D Hansten
Journal of Clinical Pharmacology|May 1, 1980
Effect of antacid and ascorbic acid on serum salicylate concentrationP D Hansten, W L Hayton
Diabetes Care|March 1, 1981
Metabolism of chlorpropamideR K Campbell, P D Hansten
Clinical Pharmacy|September 1, 1987
Effect of metoclopramide on the absorption of an oral sustained-release quinidine productG J Yuen, P D Hansten, J Collins
American Journal of Hospital Pharmacy|July 1, 1979
Drug interaction exposures in an ambulatory Medicaid populationM J Jinks, P D Hansten, J L Hirschman
Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)|April 12, 2001
ORCA: OpeRational ClassificAtion of drug interactionsP D Hansten, J R Horn, T K Hazlet
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|September 14, 2000
Cyclosporine-drug interactions and the influence of patient ageJ Lill, L A Bauer, J R Horn, et al.
Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)|April 12, 2001
Performance of community pharmacy drug interaction softwareT K Hazlet, T A Lee, P D Hansten, et al.
The Journal of Rheumatology|April 1, 1995
Nonsteroidal antiinflammatory drug discontinuation in patients with osteoarthritisD Scholes, A Stergachis, P M Penna, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 6, 1998
Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancerD C Farrow, T L Vaughan, P D Hansten, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
The Annals of Pharmacotherapy|December 1, 1993
Comment: pitfalls in reporting drug interactionsJ R Horn, P D Hansten
Journal of Clinical Pharmacology|May 1, 1980
Effect of antacid and ascorbic acid on serum salicylate concentrationP D Hansten, W L Hayton
Diabetes Care|March 1, 1981
Metabolism of chlorpropamideR K Campbell, P D Hansten
Clinical Pharmacy|September 1, 1987
Effect of metoclopramide on the absorption of an oral sustained-release quinidine productG J Yuen, P D Hansten, J Collins
American Journal of Hospital Pharmacy|July 1, 1979
Drug interaction exposures in an ambulatory Medicaid populationM J Jinks, P D Hansten, J L Hirschman
Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)|April 12, 2001
ORCA: OpeRational ClassificAtion of drug interactionsP D Hansten, J R Horn, T K Hazlet
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|September 14, 2000
Cyclosporine-drug interactions and the influence of patient ageJ Lill, L A Bauer, J R Horn, et al.
Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)|April 12, 2001
Performance of community pharmacy drug interaction softwareT K Hazlet, T A Lee, P D Hansten, et al.
The Journal of Rheumatology|April 1, 1995
Nonsteroidal antiinflammatory drug discontinuation in patients with osteoarthritisD Scholes, A Stergachis, P M Penna, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 6, 1998
Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancerD C Farrow, T L Vaughan, P D Hansten, et al.
Pageof 3